- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05378763
HER2 엑손 20 돌연변이를 보유한 국소 진행성 또는 전이성 NSCLC로 이전에 치료를 받은 참가자에서 포지오티닙에 대한 연구 (PINNACLE)
HER2 엑손 20 돌연변이(PINNACLE)가 있는 국소 진행성 또는 전이성 비소세포폐암(NSCLC) 이전에 치료를 받은 환자를 대상으로 한 포지오티닙의 무작위 3상 연구
The primary purpose of this study is to compare the progression-free survival (PFS) in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring human epidermal growth factor receptor 2 (HER2) exon 20 mutations when treated with poziotinib versus docetaxel.
연구 개요
상세 설명
This is a Phase 3, active-controlled, multicenter study to compare the efficacy and safety/tolerability of poziotinib versus docetaxel in previously treated participants with locally advanced or metastatic NSCLC harboring HER2 exon 20 mutations.
Participants will be randomized in a 2:1 ratio to:
- Arm A: Poziotinib 8 milligrams (mg), twice daily (BID) or
- Arm B: Docetaxel 75 milligrams per meter square (mg/m^2)
The Screening Period lasts up to 21 days prior to Cycle 1, Day 1 (C1D1). Participants will be treated in 21-day cycles or until disease progression, death, intolerable adverse events (AEs), initiation of non-protocol anti-cancer treatment, or other protocol-specified reasons.
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Florida
-
Winter Haven, Florida, 미국, 33880
- Bond Clinic, P.A.
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Participant must:
- Be willing and capable of providing signed and dated Informed Consent, adhering to dosing and visit schedules, and meeting the study requirements
- Have histologically or cytologically confirmed NSCLC
- Have at least one measurable NSCLC target lesion per RECIST v.1.1 by local assessment
- Participant has had at least one prior systemic treatment for locally advanced or metastatic NSCLC, including platinum and a checkpoint inhibitor (CPI) therapy, unless the investigator affirms that a CPI was not medically indicated.
- Have documentation of HER2 exon 20 mutation
- Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- Have adequate hematologic, hepatic, and renal function at Baseline as per protocol
Exclusion Criteria:
Participant:
- Has had previous treatment with poziotinib for treatment of NSCLC
- Has EGFR or anaplastic lymphoma kinase (ALK) genome tumor alterations
- Has had previous treatment with docetaxel for locally advanced or metastatic NSCLC. If docetaxel was received in the neo-adjuvant or adjuvant setting, progressive disease must have occurred ≥6 months after the last dose to be eligible
- Has spinal cord compression or leptomeningeal disease
- Has a high risk of cardiac disease, as determined by the Investigator
- Has a history of, or signs of Grade ≥2 pneumonitis on current imaging studies
- Is unable to take drugs orally
- Is pregnant or breast-feeding
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Poziotinib 8 mg
Participants will receive poziotinib 8 mg, orally, BID, in 21 day cycles or until disease progression, death, intolerable adverse events (AEs), initiation of non-protocol anti-cancer treatment, or other protocol-specified reasons for participant withdrawal from the study. |
Poziotinib tablets
다른 이름들:
|
|
활성 비교기: Docetaxel 75 mg/m^2
Participants will receive docetaxel 75 mg/m^2, intravenously (IV) on Day 1 of each 21-day treatment cycle or until disease progression, death, intolerable AEs, initiation of non-protocol anti-cancer treatment, or other protocol-specified reasons for participant withdrawal from the study. |
Docetaxel IV infusion |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression Free Survival (PFS)
기간: Up to approximately 5 years
|
PFS is defined as the time (in months) from the start of the study treatment to the date of first documented disease progression by central radiographic evaluation per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1) or death due to any cause, whichever occurs first. |
Up to approximately 5 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Overall survival (OS)
기간: Up to approximately 5 years
|
OS is defined as the time (in months) from the start of study treatment to the date of death due to any cause. |
Up to approximately 5 years
|
|
Objective Response Rate (ORR)
기간: Up to approximately 5 years
|
ORR is defined as the proportion of participants who achieve at least one complete response (CR) or partial response (PR) by the central radiographic evaluation as per the RECIST v.1.1 criteria, before disease progression. Per RECIST v.1.1 for solid tumors, CR is defined as disappearance of all tumor lesions (TLs) and disappearance or reduction of all pathological lymph nodes <10mm (short axis). PR is ≥30% decrease in sum of diameters (SOD) from Baseline. |
Up to approximately 5 years
|
|
Disease Control Rate (DCR)
기간: Up to approximately 5 years
|
DCR is defined as the proportion of participants who achieve at least one CR, PR, stable disease (SD), or non-CR/non-progressive disease (PD), by the central radiographic evaluation per the RECIST v.1.1 criteria, before disease progression. Per RECIST v.1.1 for solid tumors, CR is defined as disappearance of all tumor lesions (TLs) and disappearance or reduction of all pathological lymph nodes <10mm (short axis). PR is ≥30% decrease in sum of diameters (SOD) from Baseline, and non PD is ≥20% increase in SOD from previous smallest SOD on study, and an absolute increase of ≥5mm). SD is SOD change neither sufficient for PR nor sufficient for PD. |
Up to approximately 5 years
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- SPI-POZ-301
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .